lintuzumab   Click here for help

GtoPdb Ligand ID: 7983

Synonyms: ACTIMAB® | HuM195 | SGN-33 | SMART M195
Immunopharmacology Ligand
Compound class: Antibody
Comment: Lintuzumab is a monoclonal antibody directed against CD33, a surface antigen found on myeloid leukemia cells. A modified version of lintuzumab that is conjugated with the chelator satetraxetan to facilitate actinium (225Ac) radiolabelling (a radioimmunotherapeutic) has been developed (see Patent US6670456 [4] and IMGT/mAb-db ID 936). 225Ac emits α particles and is used as these cause less nonspecific cytotoxicity than β particles (i.e. decreased killing of bystander cells). 225Ac has been termed a 'nano-generator' as for each decay producing a high-energy α particle, a series of daughter atoms generate additional α particles, effectively amplifying the radioactive dose at the target site. Lintuzumab is a humanized version of the murine anti-CD33 antibody, M195 [2].
Click here for help
1. Actinium Pharmaceuticals Inc. 
Accessed on 24/11/2014. Modified on 24/11/2014.,
2. Caron PC, Co MS, Bull MK, Avdalovic NM, Queen C, Scheinberg DA. (1992)
Biological and immunological features of humanized M195 (anti-CD33) monoclonal antibodies.
Cancer Res, 52 (24): 6761-7. [PMID:1458463]
3. Ferlazzo G, Spaggiari GM, Semino C, Melioli G, Moretta L. (2000)
Engagement of CD33 surface molecules prevents the generation of dendritic cells from both monocytes and CD34+ myeloid precursors.
Eur J Immunol, 30 (3): 827-33. [PMID:10741398]
4. Frank RK, Kiefer GE, Simon J. (2003)
Actinium-225 complexes and conjugates for targeted radiotherapy.
Patent number: US6670456. Assignee: Dow Global Technologies Inc.. Priority date: 28/02/2001. Publication date: 30/12/2003.
5. Garnache-Ottou F, Chaperot L, Biichle S, Ferrand C, Remy-Martin JP, Deconinck E, de Tailly PD, Bulabois B, Poulet J, Kuhlein E et al.. (2005)
Expression of the myeloid-associated marker CD33 is not an exclusive factor for leukemic plasmacytoid dendritic cells.
Blood, 105 (3): 1256-64. [PMID:15388576]
6. Paul SP, Taylor LS, Stansbury EK, McVicar DW. (2000)
Myeloid specific human CD33 is an inhibitory receptor with differential ITIM function in recruiting the phosphatases SHP-1 and SHP-2.
Blood, 96 (2): 483-90. [PMID:10887109]
7. Taylor VC, Buckley CD, Douglas M, Cody AJ, Simmons DL, Freeman SD. (1999)
The myeloid-specific sialic acid-binding receptor, CD33, associates with the protein-tyrosine phosphatases, SHP-1 and SHP-2.
J Biol Chem, 274 (17): 11505-12. [PMID:10206955]
8. Ulyanova T, Blasioli J, Woodford-Thomas TA, Thomas ML. (1999)
The sialoadhesin CD33 is a myeloid-specific inhibitory receptor.
Eur J Immunol, 29 (11): 3440-9. [PMID:10556798]